Tue, 04/14/2026 - 12:45 Gizmodo In a Phase III trial, Revolution Medicines' daraxonrasib almost doubled the survival length of people with advanced pancreatic cancer. Tags health Source This Experimental Drug Could Be a Game Changer for Pancreatic Cancer
